Jazz Intends To Offer $850M Of Exchangeable Senior Notes Due 2030 In Private Offering; Plans Concurrent Ordinary Share Repurchases Up To $150M Of Its Ordinary Shares

Jazz Pharmaceuticals, together with its consolidated subsidiaries, expects to use a portion of the net proceeds to prepay up to approximately $350 million of the term loans outstanding under the credit agreement and the remainder for general corporate purposes.